AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) released its earnings results on Tuesday. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04, FiscalAI reports. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The company had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics updated its FY 2027 guidance to -0.290–0.240 EPS.

AngioDynamics Trading Down 0.2%

AngioDynamics stock opened at $12.77 on Tuesday. The company has a market capitalization of $527.66 million, a P/E ratio of -17.03 and a beta of 0.34. The firm’s fifty day simple moving average is $12.03 and its 200-day simple moving average is $11.32. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $13.99.

Institutional Investors Weigh In On AngioDynamics

A number of large investors have recently bought and sold shares of the business. Franklin Resources Inc. increased its position in AngioDynamics by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock worth $621,000 after buying an additional 1,076 shares during the last quarter. Deutsche Bank AG lifted its position in shares of AngioDynamics by 5.9% in the fourth quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after buying an additional 1,992 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of AngioDynamics during the 4th quarter worth about $27,000. Price T Rowe Associates Inc. MD boosted its stake in shares of AngioDynamics by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock worth $569,000 after acquiring an additional 2,263 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of AngioDynamics by 4.3% during the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after acquiring an additional 2,510 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Canaccord Genuity Group cut their price objective on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a report on Monday, April 6th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $18.67.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.